Lauren Santye, Assistant Editor

Top news of the day from across the health care landscape.

A genetic modification prevented neuropathy in obese mice with diabetes.

Ointment shows promise preventing neuropathy.

Less than 10% of young gay, bisexual, and other men who have sex with men have used HIV pre-exposure prophylaxis.

Non-invasive liquid biopsies may be more a more effective alternative to tissue biopsies in patients with advanced lung cancer.

Top news of the day from across the health care landscape.

Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses access to cholesterol-lowering PCSK9 inhibitors and whether the hype regarding the impact of these medications was overblown.

Clinical practice guidelines created for the treatment and diagnosis of lymphangioleiomyomatosis (LAM).

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses the out-of-pocket costs that can emerge for patients starting a specialty medication regimen.

Pevonedistat, currently being tested in clinical trials, shows promise in killing melanomas and other cancer types.

An individual’s life expectancy after initiating therapy differs among high and middle/low-income countries.

Experimental combination therapy shows a significant survival advantage over chemotherapy alone in pancreatic cancer.

Top news of the day from across the health care landscape.

National Health Checkup finds that cancer beat out infectious diseases as the biggest concern.

Exondys 51 granted accelerated approval to treat Duchenne muscular dystrophy.

Focus on the early stages of chronic obstructive pulmonary disease could prevent long-term lung function loss.

Mark Tesell, PharmD, BCPS, clinical consultant pharmacist at UMass Medical School, discusses the treatment switch from statins to PCSK9 inhibitors in patients with high cholesterol.

Top news of the day from across the health care landscape.

New strategy helps slow kidney disease progression that can occur in diabetes.

New insights pave the way for future treatment developments of pancreatic ductal adenocarcinoma.

New mouse study suggests that exposure to endocrine disrupting chemicals may cause resistance to tamoxifen therapy in some breast cancers.

Ocrelizumab (Ocrevus) may improve treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis.

Novel drug combined with gemcitabine chemotherapy shows promise

With few advancements in treatment options, a new immunotherapy treatment could lead to better outcomes in pancreatic cancer.

Top news of the day from across the healthcare landscape.

Top news of the day from across the health care landscape.

Some individuals produce antibodies that can recognize HIV.

Dopamine receptor blockers found to inhibit pancreatic tumor growth.

Mice treated with drugs that block a dopamine receptor inhibited cancer growth.

Jonathan Van Lare, PharmD, director of Clinical Services at Pharmacy Advantage, discusses the impact of oncology medications and how specialty pharmacies can adjust.